This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
BD Unveils HemoSphere Stream for Continuous Noninvasive BP Monitoring
by Zacks Equity Research
BDX launches HemoSphere Stream, enabling continuous non-invasive BP monitoring and boosting its advanced patient monitoring portfolio.
BD Rolls Out Next-Gen Medication Dispensing System Across Europe
by Zacks Equity Research
BDX rolls out AI-powered Pyxis Pro and Incada platforms in Europe, aiming to boost hospital efficiency, improve medication access and elevate patient care.
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?
by Moumi Mondal
Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.
Why Is Becton Dickinson (BDX) Down 4.5% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease
by Zacks Equity Research
BD wins CE Mark for its Revello vascular covered stent for iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market.
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
by Moumi Mondal
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.
BD Gains FDA Clearance for Surgiphor 1000mL Surgical Irrigation System
by Zacks Equity Research
BDX wins FDA 510(k) clearance for Surgiphor 1000mL antimicrobial irrigation system, expanding its surgical irrigation portfolio with a powered lavage option.
BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy
by Zacks Equity Research
BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.
BD Merges Biosciences & Diagnostics Business With Waters
by Zacks Equity Research
BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.
BD Stock Dips in Pre-Market Despite Q1 Earnings Beat, Margins Up
by Zacks Equity Research
BDX posts an earnings beat with revenue growth and expanding margins in first-quarter fiscal 2026 quarter, though adjusted profit declined year over year.